An important strategy to further reduce HIV-associated TB is to provide isoniazid preventive therapy (IPT) [8, 10], which has been demonstrated to decrease TB incidence by 27%–37% in patients receiving ART, regardless of the tuberculin skin test (TST) or interferon gamma releasing assay (IGRA) results [11–13]. This evidence concerns the gene IFNG and tuberculosis.